Next Article in Journal
Use of Corticosteroids for Remission Induction Therapy in Patients with New-Onset Ulcerative Colitis in Real-World Settings
Previous Article in Journal
Perspectives to Mitigate Payer Uncertainty in Health Technology Assessment of Novel Oncology Drugs
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 7
Issue 1
10.1080/20016689.2018.1564506
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective

by
Pierre Levy
1,
David M. Smadja
2,3,4,
Julie Dorey
5,
Mondher Toumi
6,
Anna-Katharina Meinecke
7,
Kevin Bowrin
8 and
Jean-Baptiste Briere
7,*
1
Department of Economics and Management of Health Organisations, The University of Paris Dauphine, Paris, France
2
Department of Medicine, Paris Descartes University, Sorbonne Paris City, Paris, France
3
UMR-S1140, Inserm, Paris, France
4
Hematology Department, AP-HPGeorges Pompidou European Hospital, Paris, France
5
Creativ Ceutical, Paris, France
6
Medical School, Laboratory of Public Health, The University of the Mediterranean, Marseilles, France
7
Bayer AG, Berlin, Germany
8
Bayer Plc, Reading, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1564506; https://doi.org/10.1080/20016689.2018.1564506
Submission received: 12 September 2018 / Revised: 19 December 2018 / Accepted: 21 December 2018 / Published: 1 February 2019

Abstract

Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treatment in NVAF patients from a French societal perspective. Study design: Retrospective data were obtained from 7 international normalised ratio (INR) monitoring centres in France. Patients older than 18 years of age with NVAF treated with VKA were recruited. Additional patient-level data assessing resource use corresponding with VKA treatment were collected via self-completed questionnaires. Unit costs applicable to 2015 were multiplied by resource use and summed to generate VKA treatment costs. Results: 363 patients were included; 53% were men. The majority of patients received fluindione (72%). The number of INR tests per patient per month was 1.69 (95% CI, 1.59–1.80). The monthly patient cost was €39.72 (€36.23–43.21) from the French societal perspective. Direct medical costs comprised 76% of overall costs, with drug costs representing 7.4% (€2.4); direct non-medical and indirect costs comprised 10% and 14% respectively. Conclusions: Costs associated with VKA treatment in NVAF cannot be estimated only with drug costs. When direct and indirect attributable costs associated with VKA treatment are considered, the VKA treatment costs are more substantial.
Keywords: nonvalvular atrial fibrillation; vitamin K antagonists; international normalised ratio; monitoring; resource use and costs; real-world research; France nonvalvular atrial fibrillation; vitamin K antagonists; international normalised ratio; monitoring; resource use and costs; real-world research; France

Share and Cite

MDPI and ACS Style

Levy, P.; Smadja, D.M.; Dorey, J.; Toumi, M.; Meinecke, A.-K.; Bowrin, K.; Briere, J.-B. Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective. J. Mark. Access Health Policy 2019, 7, 1564506. https://doi.org/10.1080/20016689.2018.1564506

AMA Style

Levy P, Smadja DM, Dorey J, Toumi M, Meinecke A-K, Bowrin K, Briere J-B. Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective. Journal of Market Access & Health Policy. 2019; 7(1):1564506. https://doi.org/10.1080/20016689.2018.1564506

Chicago/Turabian Style

Levy, Pierre, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin, and Jean-Baptiste Briere. 2019. "Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective" Journal of Market Access & Health Policy 7, no. 1: 1564506. https://doi.org/10.1080/20016689.2018.1564506

APA Style

Levy, P., Smadja, D. M., Dorey, J., Toumi, M., Meinecke, A. -K., Bowrin, K., & Briere, J. -B. (2019). Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective. Journal of Market Access & Health Policy, 7(1), 1564506. https://doi.org/10.1080/20016689.2018.1564506

Article Metrics

Back to TopTop